CCDC102B Antibody

What is CCDC102B and why is it important in cancer research?

CCDC102B (coiled-coil domain containing 102B) is a protein that has emerged as a significant factor in breast cancer metastasis. Research has identified CCDC102B as significantly upregulated in metastatic lesions in lymph nodes compared to matched primary tumors. Increased expression of CCDC102B has been demonstrated to promote breast cancer metastasis both in vitro and in vivo. High expression of CCDC102B correlates with poor clinical outcomes in breast cancer patients .

CCDC102B contains coiled-coil domains, which are structural motifs composed of approximately 200 amino acids that can adopt various spatial confirmations to regulate biological functions. Previous studies have shown that coiled-coil domain containing (CCDC) proteins play important roles in tumorigenesis and progression through regulation of intracellular signal transduction, transcription, cell cycle, differentiation, and apoptosis .

What are the common applications for CCDC102B antibodies in research?

CCDC102B antibodies are valuable tools for multiple experimental techniques:

These antibodies have been extensively validated through the Human Protein Atlas project, which includes testing against hundreds of normal and disease tissues .

What are the known synonyms and identifiers for CCDC102B?

When searching literature or databases for CCDC102B information, researchers should be aware of these alternative designations:

These synonyms are important when conducting comprehensive literature searches or when ordering reagents from different suppliers .

How should researchers optimize immunohistochemistry protocols for CCDC102B detection?

Optimizing IHC protocols for CCDC102B antibodies requires careful consideration of several parameters:

• Fixation and Antigen Retrieval: Studies have successfully used formalin-fixed, paraffin-embedded tissues with heat-induced epitope retrieval. The optimal pH for antigen retrieval buffer may vary between antibodies and should be tested empirically.

• Antibody Dilution Range: Commercial CCDC102B antibodies have been validated at dilutions ranging from 1:200 to 1:1000 for IHC applications .

• Detection Systems: Both chromogenic (DAB) and fluorescent secondary detection systems have been successfully employed, with selection dependent on the specific research question.

• Controls: Include positive controls (tissues known to express CCDC102B, such as breast cancer metastatic tissues) and negative controls (antibody diluent without primary antibody) in each experiment to validate results .

What are the best approaches for validating CCDC102B antibody specificity?

Thorough validation of antibody specificity is critical for reliable research outcomes:

• Western Blot Analysis: Confirm the antibody detects a band of the expected molecular weight (~46 kDa for CCDC102B).

• Immunoprecipitation followed by Mass Spectrometry: This approach can definitively identify the protein being recognized by the antibody.

• Genetic Approaches: Use CCDC102B knockout cells (via CRISPR/Cas9) or cells with CCDC102B overexpression as positive and negative controls. The CRISPR/Cas9 system has been successfully employed to generate CCDC102B knockout cells by cloning sgRNA oligos into lentiGuide-Puro vectors .

• Immunogen Competition: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining.

• Multiple Antibody Validation: Use different antibodies targeting distinct epitopes of CCDC102B to confirm findings. Commercial antibodies target different regions, such as HPA048194 (targets N-terminal region) and HPA040623 (targets middle region) .

How does CCDC102B interact with RACK1 and the NF-κB pathway in cancer progression?

Research has uncovered a complex relationship between CCDC102B, RACK1 (receptor for activated C kinase 1), and the NF-κB pathway:

• Protein Interaction: CCDC102B is stabilized by the loss of RACK1, which is negatively correlated with breast cancer metastasis. RACK1 binds to the third coiled-coil structure of CCDC102B, which includes two putative KFERQ-like motifs .

• Degradation Mechanism: RACK1 promotes CCDC102B lysosomal degradation through chaperone-mediated autophagy (CMA). Substrates containing KFERQ-like motifs are recognized by HSPA8 and then bind to LAMP2A, a CMA receptor that mediates the translocation of substrate in the lysosomal lumen for degradation .

• Pathway Activation: CCDC102B positively regulates the NF-κB pathway by interacting with RACK1. Overexpressing CCDC102B leads to less interaction between RACK1 and IKKα, thereby promoting NF-κB pathway activation .

• Experimental Approaches: To study these interactions, researchers have successfully employed:

  • Co-immunoprecipitation assays to detect protein-protein interactions

  • Mass spectrometry to identify binding partners

  • Nuclear protein extraction to assess nuclear translocation of NF-κB components

  • Immunofluorescence assays to visualize subcellular localization

What are the challenges in analyzing CCDC102B expression in patient-derived samples?

When working with clinical specimens, researchers face several challenges specific to CCDC102B analysis:

• Heterogeneity of Expression: CCDC102B expression may vary significantly between primary tumors and metastatic lesions, requiring careful sampling strategies.

• Temporal Dynamics: CCDC102B stabilization appears to be regulated by RACK1 through CMA, suggesting expression levels may fluctuate based on cellular stress and metabolic conditions.

• Correlation with Clinical Data: To meaningfully interpret CCDC102B expression levels, researchers should collect comprehensive clinical data including:

  • Lymph node status

  • Metastatic progression

  • Treatment history

  • Patient outcomes

• Standardization of Analysis: To compare results across different studies, researchers should establish standardized scoring methods for CCDC102B immunohistochemistry, considering both intensity and percentage of positive cells.

How can CRISPR/Cas9 technology be optimized for studying CCDC102B function?

The CRISPR/Cas9 system has been successfully applied in CCDC102B functional studies:

• Guide RNA Design: Effective sgRNAs targeting CCDC102B have been designed and cloned into lentiGuide-Puro vectors. For optimal results, design multiple sgRNAs targeting different exons of CCDC102B .

• Cell Line Selection: MDA-MB-231 BO-Cas9 cells have been successfully used for CCDC102B knockout studies. When selecting cell lines, consider their baseline CCDC102B expression levels and metastatic potential .

• Transduction Efficiency: Optimizing viral transduction requires determining the appropriate MOI (multiplicity of infection). Tests have been performed by spinfecting 3.5×10^5 cells with different volumes of virus to achieve an MOI of 0.3 .

• Knockout Validation: Single-cell cloning followed by Western blot confirmation has been effective for isolating CCDC102B knockout clones. After transduction, cells can be selected with puromycin (2 μg/ml) or blasticidin (5 μg/ml) for 1 week .

• In vivo Screening: For in vivo functional studies, 2×10^6 CRISPR/Cas9-modified cells (e.g., MDA-MB-231 BO-Cas9 or MDA-MB-231 BO-Cas9 lentiGuide-CRISPR cells) can be injected into immunocompromised mice via the tail vein. Bioluminescence imaging using an IVIS-200 system can monitor metastasis to the lungs .

What are the common pitfalls when working with CCDC102B antibodies and how can they be addressed?

Researchers commonly encounter several challenges when working with CCDC102B antibodies:

• Background Staining:

  • Cause: Insufficient blocking or non-specific antibody binding

  • Solution: Increase blocking time (use 5-10% normal serum from the species of the secondary antibody), optimize antibody dilution, or try different blocking reagents

• Weak or Absent Signal:

  • Cause: Insufficient antigen retrieval, low antibody concentration, or degraded epitopes

  • Solution: Optimize antigen retrieval conditions (try different buffers and pH levels), increase antibody concentration, or use fresh tissue samples

• Inconsistent Results Between Experiments:

  • Cause: Variations in fixation time, antibody batches, or detection systems

  • Solution: Standardize protocols, use the same antibody lot when possible, and include positive and negative controls in each experiment

• Non-specific Bands in Western Blot:

  • Cause: Cross-reactivity with similar proteins or degradation products

  • Solution: Increase washing stringency, optimize blocking conditions, or validate with CCDC102B overexpression and knockout controls

What are the most effective methods for quantifying CCDC102B expression levels?

Several complementary approaches can be used to quantify CCDC102B expression:

• RT-qPCR Analysis:

  • RNA can be extracted using TRIzol reagent and reverse transcribed with appropriate kits (e.g., PrimeScript RT Reagent Kit)

  • Real-time PCR can be performed with SYBR Premix Ex Taq using ACTB (beta-actin) as a reference gene

  • Calculate relative expression using the 2^(-ΔΔCt) method

• Western Blot Quantification:

  • Use appropriate loading controls (GAPDH, β-actin)

  • Employ densitometric analysis software for quantification

  • Present data as fold-change relative to control conditions

• Immunohistochemistry Scoring:

  • Implement standardized scoring systems (e.g., H-score, Allred score)

  • Consider both staining intensity and percentage of positive cells

  • Use automated image analysis software for objective quantification

• RNA-Seq Analysis:

  • Calculate expression levels according to FPKM (fragments per kilobase of transcript per million mapped reads) values

  • Use Gene Set Enrichment Analysis (GSEA) to identify pathways enriched among differentially expressed genes

How might CCDC102B serve as a therapeutic target for cancer metastasis?

Based on current understanding of CCDC102B's role in cancer progression, several therapeutic strategies could be explored:

• Targeting Protein-Protein Interactions: Disrupting the interaction between CCDC102B and RACK1 could potentially restore normal degradation of CCDC102B through chaperone-mediated autophagy.

• Enhancing CMA-mediated Degradation: Compounds that enhance CMA activity might increase CCDC102B degradation. The research shows that RACK1 promotes CCDC102B lysosomal degradation by mediating chaperone-mediated autophagy .

• NF-κB Pathway Inhibition: Since CCDC102B positively regulates the NF-κB pathway, combining CCDC102B targeting with NF-κB inhibitors might have synergistic effects.

• RNA Interference Approaches: siRNA or antisense oligonucleotides targeting CCDC102B mRNA could be explored for reducing CCDC102B expression levels.

• Monitoring as a Biomarker: Given that high expression of CCDC102B correlates with poor clinical outcomes in breast cancer patients, it could serve as a prognostic biomarker to identify patients who might benefit from more aggressive therapies .

What are the emerging techniques for studying CCDC102B subcellular localization and dynamics?

Advanced imaging and molecular techniques offer new opportunities for studying CCDC102B:

• Super-resolution Microscopy: Techniques such as STORM, PALM, or SIM could provide nanoscale resolution of CCDC102B localization, particularly in relation to centrosomes and other cellular structures.

• Live-cell Imaging: CCDC102B tagged with fluorescent proteins could enable real-time tracking of its dynamics during cell division and migration.

• Proximity Labeling Approaches: Techniques like BioID or APEX2 could identify proteins in close proximity to CCDC102B in living cells, expanding our understanding of its interactome.

• Correlative Light and Electron Microscopy (CLEM): This approach could link the fluorescence signal of labeled CCDC102B with ultrastructural details provided by electron microscopy.

• Mass Spectrometry-based Interactomics: Quantitative proteomics approaches could identify changes in CCDC102B interaction partners under different conditions or treatments.